3.3 Medication Safety & Pharmacovigilance
Key Takeaways
- High-alert medications (e.g., insulin, heparin, opioids, concentrated electrolytes) carry heightened risk of significant harm and require independent double checks and standardized processes.
- Tall Man lettering, barcode medication administration (BCMA), standardized order sets, and removal of error-prone abbreviations are core error-prevention strategies.
- Adverse drug reactions (ADRs) and product problems are reported to the FDA through MedWatch; serious vaccine events are reported to VAERS.
- A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required safety program for selected drugs whose risks require more than standard labeling.
- Continuous quality improvement (CQI) treats most errors as system failures and uses root cause analysis and just-culture principles rather than individual blame.
Why Medication Safety Matters on the NAPLEX
Medication safety threads through NAPLEX Area 2 and connects to professional practice reporting duties. The NAPLEX expects you to classify an error, choose the system control that prevents it, and know the correct reporting pathway. The guiding principle is that most errors are system failures, not isolated individual mistakes, so durable fixes change the process rather than only retraining a person.
Types of Medication Errors
- Prescribing error — wrong drug, dose, route, or a missed interaction at the ordering stage.
- Transcription/order-entry error — misread or mis-keyed order.
- Dispensing error — wrong drug, strength, or label leaving the pharmacy.
- Administration error — wrong time, route, rate, technique, or patient.
- Monitoring error — failure to track a known risk (for example, no INR follow-up on warfarin).
A near miss is an error that is caught before reaching the patient; near misses are reported and analyzed because they reveal weak points before harm occurs.
High-Alert Medications and Error Prevention
High-alert medications are drugs that bear a heightened risk of causing significant patient harm when used in error. ISMP maintains the recognized lists. Frequently tested examples:
- Insulin (all forms)
- Anticoagulants (heparin, warfarin, direct oral anticoagulants)
- Opioids (especially IV and concentrated oral)
- Concentrated electrolytes (potassium chloride, hypertonic sodium chloride)
- Chemotherapy agents
- Neuromuscular blocking agents
The error is not necessarily more likely with these drugs, but its consequence is more severe, so additional safeguards are layered on:
| Control | What It Prevents |
|---|---|
| Independent double check | Wrong dose/product of a high-alert drug |
| Tall Man lettering | Look-alike/sound-alike name confusion |
| Barcode medication administration (BCMA) | Wrong drug/patient at administration |
| Standardized order sets and concentrations | Variable, error-prone manual orders |
| Removing error-prone abbreviations | Misread orders |
| Auxiliary labels and alerts | Missed warnings and special handling |
Adverse Drug Reaction Detection and Reporting
An adverse drug reaction (ADR) is an unintended, harmful response to a drug at normal doses, distinct from a medication error (a preventable process failure). Pharmacovigilance is the science of detecting, assessing, and preventing adverse effects across a product's lifecycle.
Reporting Pathways
- FDA MedWatch — the FDA program for voluntary reporting of serious adverse events, product quality problems, and therapeutic failures for drugs and most products. Reporting is voluntary for health professionals and consumers but mandatory for manufacturers.
- Vaccine Adverse Event Reporting System (VAERS) — the dedicated system for adverse events following vaccination.
- Causality is assessed by criteria such as temporal relationship, dechallenge/rechallenge response, and biologic plausibility.
Report a serious event when the outcome is death, life-threatening, hospitalization (initial or prolonged), disability, congenital anomaly, or requires intervention to prevent permanent harm.
Risk Evaluation and Mitigation Strategies (REMS)
A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-required risk-management program for certain drugs whose serious risks require more than standard labeling to ensure benefits outweigh risks. REMS elements may include:
- A Medication Guide or patient package insert.
- A communication plan to healthcare providers.
- Elements to assure safe use (ETASU) — for example, prescriber certification, pharmacy/dispenser certification, documented safe-use conditions, patient enrollment or monitoring (such as required pregnancy testing or laboratory results before dispensing).
- An implementation system and timetable for assessment.
For an ETASU drug, the pharmacy may not dispense unless the program's conditions are verified (for example, an authorization number or confirmed enrollment). The NAPLEX tests recognition that REMS adds dispensing prerequisites beyond an ordinary prescription.
Storage, Handling, and Recalls
Safe storage and handling protect product integrity and prevent diversion and exposure:
- Temperature control — controlled room temperature, refrigeration, or freezing per labeling; cold-chain products require continuous monitoring, and excursions must be assessed before use.
- Light and moisture protection, segregation of internal vs. external products, and isolation of hazardous drugs per USP <800>.
- Look-alike/sound-alike separation and high-alert storage controls (for example, removing or sequestering concentrated electrolytes from general floor stock).
- Controlled substance security — restricted access, perpetual inventory, and required recordkeeping.
Drug Recalls
The FDA classifies recalls by risk:
| Class | Risk |
|---|---|
| Class I | Reasonable probability of serious adverse health consequences or death |
| Class II | Temporary or medically reversible adverse consequences; remote probability of serious harm |
| Class III | Unlikely to cause adverse health consequences (e.g., minor labeling defect) |
The pharmacy must identify affected lot numbers, quarantine stock, and follow the recall communication and patient-notification process appropriate to the class.
Continuous Quality Improvement (CQI)
Continuous quality improvement (CQI) is the structured, ongoing process of identifying, analyzing, and reducing medication-related risk. Core concepts the NAPLEX expects:
- Just culture — distinguishes human error and at-risk behavior (managed by coaching and system change) from reckless behavior (managed by accountability). Punitive responses to honest error suppress reporting and hide system flaws.
- Root cause analysis (RCA) — a retrospective method that asks why repeatedly to reach the underlying system cause rather than stopping at the front-line individual.
- Failure mode and effects analysis (FMEA) — a prospective method that maps where a process could fail and prioritizes high-risk failure modes before harm occurs.
- Hierarchy of controls — forcing functions and system/design changes are more reliable than education and reminders alone.
The most effective corrective action removes the opportunity for the error (for example, removing concentrated potassium chloride from floor stock) rather than relying on individual vigilance.
A pharmacist discovers that a near miss occurred: a wrong-strength insulin was caught at the final verification step before reaching the patient. Under continuous quality improvement principles, what is the best primary response?
A patient experiences a serious, unexpected adverse drug reaction to a newly approved oral medication that results in hospitalization. Which is the appropriate FDA reporting pathway?
A drug has a REMS with elements to assure safe use (ETASU) that require documented laboratory results before each dispense. A prescription arrives without that documentation. What should the pharmacist do?
The FDA issues a recall for a medication because using it has a reasonable probability of causing serious adverse health consequences or death. How is this recall classified?